In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
All content for The Analytical Wavelength is the property of ACD/Labs and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
AI and Drug Discovery - The Past, Present, and Future
The Analytical Wavelength
46 minutes
3 years ago
AI and Drug Discovery - The Past, Present, and Future
AI-assisted drug discovery is all the rage these days. It seems as if new companies and partnerships are being announced every day. Is this a new phenomenon, or an evolution of what has been done in the past? What are the key challenges standing in the way of computer-assisted drug discovery?For the last episode of season 2 of the analytical wavelength we talk with two experts in drug discovery. Dr. Chris Lipinski is famous for introducing the "Lipinski Rule of 5s," the original prediction to...
The Analytical Wavelength
In this episode, ACD/Labs Vice President of Innovation and Informatics Strategy, Andrew Anderson, and Strategic Partnerships Director, Graham McGibbon continue their discussion on digitalization and digital transformation in the context of pharmaceutical R&D. They assess how well the industry is adapting to the current digital landscape, and what can be done to contribute to the overall digitalization process.Andrew and Graham also share their thoughts on how digitalization can be used al...
